- Adastra Holdings (XTRX) has filed its consolidated financial statements and related MD&A for the three and nine months ended September 30, 2021, and 2020
- Revenue of approximately $1.8 million compared to approximately $1.2 million in Q2 2021
- Gross profit of approximately $934,000 in Q3 2021 nearly doubled from Q2 2021
- Net loss decreased to approximately $208,000 compared to approximately $510,000 in Q2 2021
- Adastra is a manufacturer and supplier of innovative ethnobotanical and cannabis science products designed for the adult-use and medical markets
- Adastra Holdings Ltd. (XTRX) opened trading at C$0.92 per share
Adastra Holdings (XTRX) has filed its consolidated financial statements and related MD&A for the three and nine months ended September 30, 2021, and 2020.
CEO Michael Forbes sat down with Caroline Egan to discuss the results.
Q3 2021 highlights
- Revenue of approximately $1.8 million compared to approximately $1.2 million in Q2 2021, a 46 per cent increase.
- On a year-to-date basis, revenue increased $2.4 million, or 190 per cent, versus last year
- Distillate production (grams) increased 275 kg, or 190 per cent, year-to-date and 56 kg, or 86 per cent, in Q3 2021 compared to last year
- Gross profit of approximately $934,000 in Q3 2021 nearly doubled from Q2 2021, with gross margins expanding to 52 per cent over the same period
- Net loss narrowed to approximately $208,000 compared to approximately $510,000 in Q2 2021
- Net increase in cash of approximately $62,000 in the first nine months of 2021
- Refinancing of mortgage facility to provide incremental $1.0 million of liquidity
Michael Forbes, Chief Executive Officer of Adastra, commented on the results.
“I am very excited about the future of Adastra and how hard the team has worked in restructuring and reducing costs. We are hitting our stride in Q4, positioning us for rapid growth and positive cash flow in the upcoming quarter. We have a large national sales footprint that we are leveraging into new products, particularly infused pre-rolls, which we believe we can quickly turn newly introduced products into high revenue generators. I am confident that our sales will be brisk and help us achieve $5 million in monthly sales by the end of 2022.”
“Our business is showing strong momentum sequentially from Q2 2021 to Q3 2021,” added Forbes.
“This is highlighted by an 18 per cent increase in sales to provinces, including 107% growth in Ontario, and the entrance during the quarter into Yukon, our sixth province. In addition, after introducing a new line of shatter vaporizer cartridges over the summer, we have taken this category from no revenue in Q1 to over $400,000 in Q3 2021, growth we believe is due to our dominant shelf space across Canada.”
“Strategically, our focus remains on the following growth areas: medical extraction, premium branded extraction products, flower products, drug formulation, sales force expansion, and global. We are particularly excited about the upcoming launch of infused pre-rolls, one of the fastest growing categories of cannabis products in both Canada and the U.S. As we are doing with shatter, we plan to leverage our shelf space to sell into the provinces, and expect that this category to ultimately be a larger contributor.”
“Combined, these efforts and financial results give us optimism as we approach 2022,” concluded Forbes. “We believe we have established a platform for profitable growth, with multiple revenue streams and differentiation in the marketplace. We look to leverage this platform over the coming months to create sustainable value for our customers, partners, and shareholders.”
Formerly known as Phyto Extractions Inc., Adastra is a leading manufacturer and supplier of innovative ethnobotanical and cannabis science products designed for the adult-use and medical markets.
Adastra Holdings Ltd. (XTRX) opened trading at C$0.92 per share.
